Literature DB >> 27059342

Sleep-Related Epilepsy.

Mar Carreño1, Santiago Fernández2.   

Abstract

OPINION STATEMENT: Sleep has a strong influence on interictal epileptiform discharges and on epileptic seizures. Interictal epileptiform discharges are activated by sleep deprivation and sleep, and some epilepsies occur almost exclusively during sleep. Treatment of sleep-related epilepsy should take in account the type of epileptic syndrome, the type of seizures, the patient characteristics, and also the pharmacokinetics of the drug. Proper characterization of the epilepsy is essential to choose appropriate antiepileptic drugs. Drugs effective in focal epilepsy may be used to treat benign genetic focal epilepsies such as rolandic epilepsy and other focal (frontal or not) sleep epilepsies. These include both classical (such as carbamazepine) and new (such as levetiracetam and lacosamide) antiepileptic drugs. Drug-resistant cases should be evaluated for epilepsy surgery, which may be efficacious in this setting. Valproate, lamotrigine, topiramate, levetiracetam, and perampanel are effective against generalized tonic-clonic seizures in genetic generalized epilepsies, which frequently happen on awakening. Risks of valproate should be considered before prescribing it to women of childbearing age. Specific syndromes such as ESES require specific treatment such as a combination of high dose steroids, benzodiazepines, levetiracetam, and even surgery when an epileptogenic lesion is present. Sleep disorders that may worsen epilepsy such as obstructive sleep apnea or insomnia should be adequately treated to improve seizure frequency. Adequate control of seizures during sleep (especially generalized tonic-clonic seizures) decreases risk of sudden unexpected death in epilepsy (SUDEP).

Entities:  

Keywords:  Awakening; Epilepsy; Nocturnal; Obstructive sleep apnea; Sleep; Treatment

Year:  2016        PMID: 27059342     DOI: 10.1007/s11940-016-0402-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  60 in total

1.  Oxcarbazepine in nocturnal frontal-lobe epilepsy: a further interesting report.

Authors:  Andrea Romigi; Maria G Marciani; Fabio Placidi; Laura R Pisani; Francesca Izzi; Federico Torelli; Chiara Prosperetti
Journal:  Pediatr Neurol       Date:  2008-10       Impact factor: 3.372

2.  Relationship of epileptic seizures to sleep stage and sleep depth.

Authors:  Daniela Minecan; Alamelu Natarajan; Mary Marzec; Beth Malow
Journal:  Sleep       Date:  2002-12       Impact factor: 5.849

3.  Which electroencephalography (EEG) for epilepsy? The relative usefulness of different EEG protocols in patients with possible epilepsy.

Authors:  J P Leach; L J Stephen; C Salveta; M J Brodie
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-26       Impact factor: 10.154

4.  Epilepsy and obstructive sleep apnea.

Authors:  Peter Hollinger; Ramin Khatami; Matthias Gugger; Christian W Hess; Claudio L Bassetti
Journal:  Eur Neurol       Date:  2006-03-24       Impact factor: 1.710

5.  Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures.

Authors:  Irene García-Morales; Rafael Toledano Delgado; Mercé Falip; Dulce Campos; María Eugenia García; Antonio Gil-Nagel
Journal:  Seizure       Date:  2011-09-13       Impact factor: 3.184

6.  Drug-resistant focal sleep related epilepsy: results and predictors of surgical outcome.

Authors:  Anna Losurdo; Paola Proserpio; Francesco Cardinale; Francesca Gozzo; Laura Tassi; Roberto Mai; Stefano Francione; Laura Castana; Giorgio Lo Russo; Giuseppe Casaceli; Ivana Sartori; Giacomo Della Marca; Massimo Cossu; Lino Nobili
Journal:  Epilepsy Res       Date:  2014-03-12       Impact factor: 3.045

7.  Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.

Authors:  S Noachtar; E Andermann; P Meyvisch; F Andermann; W B Gough; J Schiemann-Delgado
Journal:  Neurology       Date:  2008-02-19       Impact factor: 9.910

8.  Oxcarbazepine in children with nocturnal frontal-lobe epilepsy.

Authors:  G Praveen Raju; Dean P Sarco; Annapurna Poduri; James J Riviello; Ann Marie R Bergin; Masanori Takeoka
Journal:  Pediatr Neurol       Date:  2007-11       Impact factor: 3.372

9.  Nicotine as an antiepileptic agent in ADNFLE: an N-of-one study.

Authors:  John O Willoughby; Kenneth J Pope; Vaughn Eaton
Journal:  Epilepsia       Date:  2003-09       Impact factor: 5.864

10.  Treatment for continuous spikes and waves during sleep (CSWS): survey on treatment choices in North America.

Authors:  Iván Sánchez Fernández; Kevin Chapman; Jurriaan M Peters; Jacquelyn Klehm; Michele C Jackson; Anne T Berg; Tobias Loddenkemper
Journal:  Epilepsia       Date:  2014-06-10       Impact factor: 5.864

View more
  4 in total

1.  Daylight saving time transitions are not associated with increased seizure incidence.

Authors:  Logan D Schneider; Robert E Moss; Daniel M Goldenholz
Journal:  Epilepsia       Date:  2019-03-19       Impact factor: 5.864

2.  Loss of CLOCK Results in Dysfunction of Brain Circuits Underlying Focal Epilepsy.

Authors:  Peijun Li; Xiaoqin Fu; Nathan A Smith; Julie Ziobro; Julian Curiel; Milagros J Tenga; Brandon Martin; Samuel Freedman; Christian A Cea-Del Rio; Livio Oboti; Tammy N Tsuchida; Chima Oluigbo; Amanda Yaun; Suresh N Magge; Brent O'Neill; Amy Kao; Tesfaye G Zelleke; Dewi T Depositario-Cabacar; Svetlana Ghimbovschi; Susan Knoblach; Chen-Ying Ho; Joshua G Corbin; Howard P Goodkin; Stefano Vicini; Molly M Huntsman; William D Gaillard; Gregorio Valdez; Judy S Liu
Journal:  Neuron       Date:  2017-10-11       Impact factor: 17.173

3.  The Cyclic Vomiting Syndrome Threshold: A Framework for Understanding Pathogenesis and Predicting Successful Treatments.

Authors:  David J Levinthal
Journal:  Clin Transl Gastroenterol       Date:  2016-10-27       Impact factor: 4.488

Review 4.  Sleep Disruption Worsens Seizures: Neuroinflammation as a Potential Mechanistic Link.

Authors:  Herlinda Bonilla-Jaime; Helena Zeleke; Asheebo Rojas; Claudia Espinosa-Garcia
Journal:  Int J Mol Sci       Date:  2021-11-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.